metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA) 3
mHCC - 1st line (L1) 10
mHCC - 2nd line (L2) 2
lung cancer : non small cell (NSCLC) 5

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
sintilimab based treatment
sintilimab
Immune checkpoint association
nivolumab plus ipilimumab

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open